Cantor Fitzgerald has a “Overweight” rating and a $7.00 price objective on the stock. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share. Get ...

Cantor Fitzgerald currently has a “Overweight” rating and a $46.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share ...

Cantor Fitzgerald announces it will be expanding it's Bitcoin financing services in the wake of Trump administration changes. Reflecting the United States’ growing embrace of Bitcoin, investment bank ...

Investment banking firm Cantor Fitzgerald has selected Anchorage Digital and Copper as its Bitcoin custodians and collateral managers as it launches its new digital asset financing business ...

Since ending in correction territory last week, Wall Street has rebounded, and Cantor Fitzgerald believes this rally could extend through to the end of the month. However, despite the potential ...

Friday - Summit Therapeutics plc (NASDAQ:SMMT) stock received a new Overweight rating from Cantor Fitzgerald, signaling a positive outlook from the firm. The coverage initiation by Cantor ...

On Friday, Cantor Fitzgerald reiterated its Overweight rating on Compass Pathways plc (NASDAQ:CMPS), a life sciences company focused on developing psilocybin therapy for mental health conditions.

Fintel reports that on March 19, 2025, Cantor Fitzgerald upgraded their outlook for Tesla (SNSE:TSLA) from Neutral to Overweight. There are 5,232 funds or institutions reporting positions in Tesla.

Global Head of Cantor Fitzgerald Asset Management. "This growth underscores our commitment to creating lasting economic impact and revitalizing neighborhoods across the United States. We are ...

Tesla (NASDAQ:TSLA) attracted an upgrade from Cantor Fitzgerald on Wednesday after the firm visited the company's Gigafactory and AI data centers in Austin. The firm moved Tesla (NASDAQ ...

In a report released today, Andres Sheppard from Cantor Fitzgerald maintained a Buy rating on Ouster (OUST – Research Report), with a price target of $11.00. The company’s shares closed ...